RxDoctor Payments Data

Brian Calhoun, MD

Family Medicine · Monroe, LANPI 1780697227

Payments from drug & device makers

$1,431in general payments, 2019–2025

Across 96 payments — averaging $14.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$223
  • Pfizer$156
  • Novo Nordisk$131
  • Kowa Pharmaceuticals America, Inc.$127
  • Teva Pharmaceuticals USA, Inc.$116
  • E.r. Squibb & Sons, L.L.C.$115
  • plus $563 from 13 others

What the payments were for

  • Food & beverage$1,427100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,431 in reported general payments places this provider in the 60th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$204,551
Medicare patients
472
Services billed
5,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$110,651
MounjaroTirzepatide101$99,008
EliquisApixaban113$78,780
RybelsusSemaglutide26$45,019
JanuviaSitagliptin Phosphate55$36,260
XareltoRivaroxaban50$35,908
JardianceEmpagliflozin29$23,826
MyrbetriqMirabegron27$19,014
FarxigaDapagliflozin Propanediol13$15,950
Repatha SureclickEvolocumab19$15,848
Stiolto RespimatTiotropium Br/Olodaterol Hcl31$15,465
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$15,425
Potassium Chloride284$13,418
LinzessLinaclotide18$13,328
Tresiba Flextouch U-200Insulin Degludec18$10,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$131$155,670132 claims
Lilly USA, LLCMounjaro$72$99,008101 claims
PfizerEliquis$156$78,780113 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$41$47,86472 claims
MerckJanuvia, Janumet Xr$87$43,28868 claims
AstraZenecaFarxiga, Symbicort$223$19,37628 claims
AbbVieLinzess, Synthroid$52$16,23570 claims
GSKTrelegy Ellipta$17$15,42517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →